Literature DB >> 24577792

Testing for efficacy in adaptive clinical trials with enrichment.

Samuel S Wu1, Yi-Hsuan Tu, Ying He.   

Abstract

Adaptive design of clinical trials has attracted considerable interest because of its potential of reducing costs and saving time in the clinical development process. In this paper, we consider the problem of assessing the effectiveness of a test treatment over a control by a two-arm randomized clinical trial in a potentially heterogenous patient population. In particular, we study enrichment designs that use accumulating data from a clinical trial to adaptively determine patient subpopulation in which the treatment effect is eventually assessed. A hypothesis testing procedure and a lower confidence limit are presented for the treatment effect in the selected patient subgroups. The performances of the new methods are compared with existing approaches through a simulation study.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  clinical trial; enrichment; hypothesis test; lower confidence limit; two-stage design

Mesh:

Year:  2014        PMID: 24577792      PMCID: PMC4362733          DOI: 10.1002/sim.6127

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  9 in total

1.  The price of innovation: new estimates of drug development costs.

Authors:  Joseph A DiMasi; Ronald W Hansen; Henry G Grabowski
Journal:  J Health Econ       Date:  2003-03       Impact factor: 3.883

2.  Drug development cost estimates hard to swallow.

Authors:  Roger Collier
Journal:  CMAJ       Date:  2009-02-03       Impact factor: 8.262

3.  Use of genomic signatures in therapeutics development in oncology and other diseases.

Authors:  R Simon; S-J Wang
Journal:  Pharmacogenomics J       Date:  2006 May-Jun       Impact factor: 3.550

4.  Interval estimation in two-stage, drop-the-losers clinical trials with flexible treatment selection.

Authors:  Dan Neal; George Casella; Mark C K Yang; Samuel S Wu
Journal:  Stat Med       Date:  2011-08-08       Impact factor: 2.373

5.  Evaluating treatments when a gender by treatment interaction may exist.

Authors:  E Russek-Cohen; R M Simon
Journal:  Stat Med       Date:  1997-02-28       Impact factor: 2.373

6.  Optimizing randomized trial designs to distinguish which subpopulations benefit from treatment.

Authors:  M Rosenblum; M J Van der Laan
Journal:  Biometrika       Date:  2011-12       Impact factor: 2.445

7.  An aid to data monitoring in long-term clinical trials.

Authors:  M Halperin; K K Lan; J H Ware; N J Johnson; D L DeMets
Journal:  Control Clin Trials       Date:  1982-12

8.  Adaptive patient enrichment designs in therapeutic trials.

Authors:  Sue-Jane Wang; H M James Hung; Robert T O'Neill
Journal:  Biom J       Date:  2009-04       Impact factor: 2.207

9.  Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset.

Authors:  Sue-Jane Wang; Robert T O'Neill; H M James Hung
Journal:  Pharm Stat       Date:  2007 Jul-Sep       Impact factor: 1.894

  9 in total
  2 in total

Review 1.  Successful aging: Advancing the science of physical independence in older adults.

Authors:  Stephen D Anton; Adam J Woods; Tetso Ashizawa; Diana Barb; Thomas W Buford; Christy S Carter; David J Clark; Ronald A Cohen; Duane B Corbett; Yenisel Cruz-Almeida; Vonetta Dotson; Natalie Ebner; Philip A Efron; Roger B Fillingim; Thomas C Foster; David M Gundermann; Anna-Maria Joseph; Christy Karabetian; Christiaan Leeuwenburgh; Todd M Manini; Michael Marsiske; Robert T Mankowski; Heather L Mutchie; Michael G Perri; Sanjay Ranka; Parisa Rashidi; Bhanuprasad Sandesara; Philip J Scarpace; Kimberly T Sibille; Laurence M Solberg; Shinichi Someya; Connie Uphold; Stephanie Wohlgemuth; Samuel Shangwu Wu; Marco Pahor
Journal:  Ageing Res Rev       Date:  2015-10-14       Impact factor: 10.895

2.  Two-stage adaptive enrichment design for testing an active factor.

Authors:  A Adam Ding; Samuel S Wu; Natalie E Dean; Rachel S Zahigian
Journal:  J Biopharm Stat       Date:  2019-05-28       Impact factor: 1.051

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.